On-Demand Webinar: Right First Time Optimising API Form for a Seamless Journey from Lab to Life

The pharmaceutical industry continues to face significant preclinical challenges, with many molecules affected by poor solubility, unstable solid forms, unpredictable bioavailability, and limited developability insight.

When the relationship between molecular structure, physical form, and process is not understood early, issues such as inappropriate salt choice or unworkable physical properties often surface too late—causing delays, rework, and costly changes to non-clinical and early clinical plans. 

In this on‑demand webinar, Dr. Stephen Byard, Principal Research Fellow, and Dr. Darren Matthews, Associate Science Director at Charles River Laboratories, share practical, science‑driven strategies to address these risks. Discover how early characterisation of physicochemical, biopharmaceutical, and stability properties can reduce uncertainty, enable smarter formulation decisions, and accelerate the path to the clinic.

Key takeaways:

• Discover the key challenges in preclinical development and how early insight into compound properties can reduce uncertainty and drive smoother study execution.
• Learn how physicochemical, biopharmaceutical, and stability data shape smarter formulation decisions and enable a faster, lower‑risk transition into the clinic.
• Recognise critical red flags in drug substance and proto‑formulation developability and understand how to optimise them for clinical and commercial success.
• Gain a holistic view of how molecular and bulk API properties influence formulation, manufacturability, in vivo performance, and the value of integrating CMC with clinical studies.